Providence Capital Advisors’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $4.99M | Buy |
82,338
+2,265
| +3% | +$132K | 0.82% | 53 |
|
|
2025
Q4 | $4.32M | Buy |
80,073
+2,757
| +4% | +$133K | 0.73% | 54 |
|
|
2025
Q3 | $3.49M | Buy |
77,316
+2,429
| +3% | +$113K | 0.6% | 57 |
|
|
2025
Q2 | $3.47M | Buy |
74,887
+21,675
| +41% | +$1.06M | 0.64% | 62 |
|
|
2025
Q1 | $3.25M | Buy |
53,212
+732
| +1% | +$42.7K | 0.67% | 61 |
|
|
2024
Q4 | $2.97M | Buy |
52,480
+221
| +0.4% | +$12.3K | 0.6% | 67 |
|
|
2024
Q3 | $2.7M | Buy |
52,259
+276
| +0.5% | +$12.9K | 0.54% | 73 |
|
|
2024
Q2 | $2.16M | Buy |
51,983
+797
| +2% | +$35.7K | 0.47% | 76 |
|
|
2024
Q1 | $2.78M | Buy |
51,186
+14,645
| +40% | +$746K | 0.61% | 70 |
|
|
2023
Q4 | $1.87M | Sell |
36,541
-1,643
| -4% | -$86.2K | 0.45% | 76 |
|
|
2023
Q3 | $2.22M | Buy |
38,184
+902
| +2% | +$55.3K | 0.58% | 71 |
|
|
2023
Q2 | $2.38M | Buy |
37,282
+626
| +2% | +$42K | 0.6% | 68 |
|
|
2023
Q1 | $2.54M | Buy |
36,656
+674
| +2% | +$47.5K | 0.67% | 63 |
|
|
2022
Q4 | $2.59M | Sell |
35,982
-37
| -0.1% | -$2.79K | 0.7% | 64 |
|
|
2022
Q3 | $2.56M | Buy |
36,019
+629
| +2% | +$45.6K | 0.77% | 60 |
|
|
2022
Q2 | $2.74M | Buy |
35,390
+1,355
| +4% | +$103K | 0.8% | 61 |
|
|
2022
Q1 | $2.48M | Buy |
34,035
+2,389
| +8% | +$160K | 0.61% | 69 |
|
|
2021
Q4 | $1.97M | Buy |
31,646
+1,462
| +5% | +$85.8K | 0.54% | 69 |
|
|
2021
Q3 | $1.79M | Buy |
30,184
+2,142
| +8% | +$141K | 0.56% | 68 |
|
|
2021
Q2 | $1.87M | Buy |
28,042
+2,594
| +10% | +$169K | 0.61% | 63 |
|
|
2021
Q1 | $1.61M | Buy |
25,448
+1,577
| +7% | +$98.1K | 0.58% | 64 |
|
|
2020
Q4 | $1.48M | Buy |
23,871
+4,071
| +21% | +$250K | 0.61% | 63 |
|
|
2020
Q3 | $1.19M | Buy |
19,800
+439
| +2% | +$26.4K | 0.63% | 58 |
|
|
2020
Q2 | $1.14M | Buy |
19,361
+19,261
| +19,261% | +$1.15M | 0.65% | 62 |
|
|
2020
Q1 | $6K | Hold |
100
| – | – | ﹤0.01% | 193 |
|
|
2019
Q4 | $6K | Hold |
100
| – | – | ﹤0.01% | 199 |
|
|
2019
Q3 | $5K | Sell |
100
-54,300
| -100% | -$2.55M | ﹤0.01% | 192 |
|
|
2019
Q2 | $2.47M | Buy |
54,400
+7,900
| +17% | +$368K | 1.46% | 32 |
|
|
2019
Q1 | $2.22M | Buy |
46,500
+5,000
| +12% | +$249K | 1.4% | 30 |
|
|
2018
Q4 | $2.16M | Buy |
41,500
+4,200
| +11% | +$226K | 1.48% | 17 |
|
|
2018
Q3 | $2.32M | Buy |
37,300
+36,900
| +9,225% | +$2.19M | 1.51% | 19 |
|
|
2018
Q2 | $22K | Sell |
400
-400
| -50% | -$21.6K | 0.02% | 151 |
|
|
2018
Q1 | $51K | Sell |
800
-67
| -8% | -$4.31K | 0.04% | 118 |
|
|
2017
Q4 | $53K | Buy |
+867
| New | +$54.2K | 0.04% | 117 |
|
Other funds holding BMY
VCM
VPM
Providence Capital Advisors's BMY Position: Q1 2026 in Review
Providence Capital Advisors increased its Bristol-Myers Squibb (BMY) stake by 2.8% in Q1 2026, buying an estimated $132K and bringing the position to 82,338 shares worth $4.99M. The position accounts for 0.82% of the portfolio, ranked #53.
Providence Capital Advisors first reported a position in BMY in Q4 2017 and has held it in 34 quarters since. 2,518 funds tracked by Wall St. Rank hold BMY as of Q1 2026.
- Providence Capital Advisors held 82,338 shares of Bristol-Myers Squibb worth $4.99M as of Q1 2026.
- Providence Capital Advisors bought 2,265 Bristol-Myers Squibb shares in Q1 2026, an estimated $132K.
- Bristol-Myers Squibb made up 0.82% of Providence Capital Advisors's portfolio in Q1 2026, its #53 holding.
- Providence Capital Advisors first reported a position in Bristol-Myers Squibb in Q4 2017 and has held it in 34 quarters since.
- 2,518 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.
Based on Providence Capital Advisors's 13F filing for Q1 2026, filed 14 May 2026.